Erratum to: The evidence on tiotropium bromide in asthma: from the rationale to the bedside

Erratum to: The evidence on tiotropium bromide in asthma: from the rationale to the bedside

Authors

  • Dejan Radovanovic Department of Biomedical and Clinical Sciences (DIBIC), University of Milan, Pulmonary Unit, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Milan
  • Pierachille Santus Department of Biomedical and Clinical Sciences (DIBIC), University of Milan, Pulmonary Unit, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Milan
  • Francesco Blasi Department of Pathophysiology and Transplantation, University of Milan, Cardio-thoracic unit and Adult Cystic Fibrosis Center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan
  • Marco Mantero Department of Pathophysiology and Transplantation, University of Milan, Cardio-thoracic unit and Adult Cystic Fibrosis Center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan
DOI: https://doi.org/10.4081/mrm.2017.244

Keywords:

Erratum

Abstract

After publication of the Review article it was brought to our attention that the sentence at the bottom of the section entitled Tiotropium bromide must be corrected as follows: “Following positive large efficacy and safety trials in asthma, in 2014 the European Medicines Agency has extended the indication of tiotropium Respimat®....

Downloads

Published

17-07-2017

Issue

Vol. 12 (2017)

Section

Erratum

License

Mattioli 1885 has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.

How to Cite

1.
Radovanovic D, Santus P, Blasi F, Mantero M. Erratum to: The evidence on tiotropium bromide in asthma: from the rationale to the bedside. Multidiscip Respir Med [Internet]. 2017 Jul. 17 [cited 2024 Jul. 4];12(1). Available from: https://mrmjournal.org/index.php/mrm/article/view/244
Crossref
Scopus
Google Scholar
Europe PMC